Bipolar Disorder - Pipeline Insight, 2024

Bipolar Disorder - Pipeline Insight, 2024

DelveInsight’s, “Bipolar Disorder - Pipeline Insight, 2024,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Bipolar Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bipolar Disorder Understanding

Bipolar Disorder: Overview

Bipolar disorder is a brain disorder that causes changes in a person's mood, energy, and ability to function. People with bipolar disorder experience intense emotional states that typically occur during distinct periods of days to weeks, called mood episodes. These mood episodes are categorized as manic/hypomanic (abnormally happy or irritable mood) or depressive (sad mood). People with bipolar disorder generally have periods of neutral mood as well. When treated, people with bipolar disorder can lead full and productive lives. People without bipolar disorder experience mood fluctuations as well. However, these mood changes typically last hours rather than days. Also, these changes are not usually accompanied by the extreme degree of behavior change or difficulty with daily routines and social interactions that people with bipolar disorder demonstrate during mood episodes. Bipolar disorder can disrupt a person’s relationships with loved ones and cause difficulty in working or going to school. Bipolar disorder is a category that includes three different diagnoses: bipolar I, bipolar II, and cyclothymic disorder. Bipolar disorder commonly runs in families: 80 to 90 percent of individuals with bipolar disorder have a relative with bipolar disorder or depression. Environmental factors such as stress, sleep disruption, and drugs and alcohol may trigger mood episodes in vulnerable people. Though the specific causes of bipolar disorder within the brain are unclear, an imbalance of brain chemicals is believed to lead to dysregulated brain activity. The average age of onset is 25 years old.

""Bipolar Disorder - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bipolar Disorder pipeline landscape is provided which includes the disease overview and Bipolar Disorder treatment guidelines. The assessment part of the report embraces, in depth Bipolar Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bipolar Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Bipolar Disorder.
• In the coming years, the Bipolar Disorder market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Bipolar Disorder R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Bipolar Disorder treatment market. Several potential therapies for Bipolar Disorder are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Bipolar Disorder market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Bipolar Disorder) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Bipolar Disorder Emerging Drugs Chapters

This segment of the Bipolar Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bipolar Disorder Emerging Drugs

• Iloperidone: Vanda Pharmaceuticals

Iloperidone is a dual-acting dopamine and serotonin receptor antagonist, developed originally by Titan Pharmaceuticals as a new treatment for schizophrenia. For several years Novartis Pharma held the worldwide development and marketing rights to iloperidone, but the company relinquished these rights in 2003. Subsequently, the rights were taken up by Vanda Pharmaceuticals. Under the license agreement from Novartis, Vanda Pharmaceuticals undertook to pursue the iloperidone Phase III development programme and complete product registration. The FDA approved iloperidone in May 2009 for treatment of schizophrenia in elderly people. Iloperidone has been launched on the market under the brand name Fanapt. Vanda is now studying Fanapt in bipolar disorder in a phase III trial, and working to develop a long-acting injection of the drug.

• RP5063: Reviva Pharmaceuticals

RP5063 is a novel atypical antipsychotic drug (APD) with relatively unique pharmacology. Its principal action is potent dopamine-serotonin stabilization, the result of partial agonist properties at dopamine (DA) D, D , and D receptors, serotonin (5-HT) 5-HT and 5-HT , and antagonist activity at 5-HT , 5-HT and 5-HT receptors. The multi-receptor profile of RP5063 includes a number of mechanisms which have the potential to improve cognitive impairments in neuropsychiatric and neurological diseases, particularly partial agonism 5-HT and 5-HT receptor antagonism, and possibly D partial agonism. RP5063 is an orally active new chemical entity (NCE) having effective patent life until September 2030 with possibility of patent term extension upto additional 5 years.

Further product details are provided in the report……..

Bipolar Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Bipolar Disorder drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Bipolar Disorder

There are approx. 22+ key companies which are developing the therapies for Bipolar Disorder. The companies which have their Bipolar Disorder drug candidates in the most advanced stage, i.e. phase III include, Vanda Pharmaceuticals.

• Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Bipolar Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bipolar Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bipolar Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bipolar Disorder drugs.

Bipolar Disorder Report Insights

• Bipolar Disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bipolar Disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bipolar Disorder drugs?
• How many Bipolar Disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bipolar Disorder?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bipolar Disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bipolar Disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vanda Pharmaceuticals
• Reviva Pharmaceuticals
• SK BIOPHARMACEUTICALS
• Pear Therapeutics
• Arvelle Therapeutics
• Janssen Research & Development
• Sunovion Pharmaceuticals
• Lyndra Therapeutics
• ILTOO Pharma
• COMPASS Pathways
• NRx Pharmaceuticals
• Carlsson Research AB
• Sunovion
• SAGE Therapeutics
• Alzamend Neuro
• OWP Pharmaceuticals
• Entheogenix Biosciences

Key Products

• Iloperidone
• RP5063
• SKL-PSY
• Pear-017
• Cenobamate
• JNJ-18038683
• SEP 378608
• LYN-005
• JNJ-55308942
• ILT101
• Psilocybin
• NRX-101
• OSU6162
• SEP-4199
• Zuranolone
• AL001
• Quetiapine oral suspension